Research teams link response to Iressa to mutations in EGF receptor.
SPOREs hammer out research agenda, seek $50,000 from NCI for further tissue analysis.
Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.
NCI blocked groups from phase III Iressa studies.
Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.
Robert Hall appointed government relations director for National Coalition for Cancer Survivorship.
Funding opportunities listed.
April issue of Business & Regulatory Report included (8 additional pages).
Trending Stories
- “All in Her Head” catalogs the history of medicine’s atrocities against women
- CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data
- Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored
Three reprimands later, he retains leadership—and mentorship—positions - Chernobyl: a 35 year follow up on long-term health effects
- How a Georgetown med school student found her calling in surgery, law, and health equity
- The unKOOL, unfiltered history of menthol cigarettes